Short Interest in Inventiva S.A. (NASDAQ:IVA) Declines By 12.1%

Inventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 347,400 shares, a decline of 12.1% from the April 30th total of 395,400 shares. Based on an average trading volume of 15,800 shares, the days-to-cover ratio is presently 22.0 days. Approximately 1.0% of the shares of the stock are short sold.

Inventiva Stock Performance

IVA stock traded up $0.11 during trading on Friday, hitting $3.52. The company had a trading volume of 86,072 shares, compared to its average volume of 64,881. The firm has a 50-day moving average price of $3.38 and a 200-day moving average price of $2.85. Inventiva has a 12 month low of $1.53 and a 12 month high of $4.05.

Analyst Ratings Changes

Several brokerages have recently commented on IVA. TD Cowen began coverage on Inventiva in a report on Friday, February 21st. They issued a "buy" rating and a $10.00 target price on the stock. Guggenheim reduced their target price on Inventiva from $12.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, April 4th. Finally, HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Inventiva in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in Inventiva S.A. (NASDAQ:IVA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,715 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.